

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for April 2026

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Pharmaris Canada Inc.	PRZ-Nebivolol	Bystolic	NEBIVOLOL HCL	2.5 mg	tablet	02548704
Pharmaris Canada Inc.	PRZ-Nebivolol	Bystolic	NEBIVOLOL HCL	5 mg	tablet	02548712
Pharmaris Canada Inc.	PRZ-Nebivolol	Bystolic	NEBIVOLOL HCL	10 mg	tablet	02548720
Pharmaris Canada Inc.	PRZ-Nebivolol	Bystolic	NEBIVOLOL HCL	20 mg	tablet	02548739
Apotex Inc.	Apo-Enzalutamide	Xtandi	ENZALUTAMIDE	40 mg	capsule	02562677
Auro Pharma Inc.	Auro-Enzalutamide	Xtandi	ENZALUTAMIDE	40 mg	capsule	02494736

Ambicare Pharmaceuticals Inc.	AMB-Cyproterone Acetate/ Ethinyl Estradiol	Diane-35	CYPROTERONE ACETATE & ETHINYL ESTRADIOL	2 mg/ 0.035 mg	tablet	02564424
Taro Pharmaceuticals Inc.	Taro-Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	70 mg	capsule	02558777
Dr. Reddy's Laboratories Ltd.	Reddy-Enzalutamide	Xtandi	ENZALUTAMIDE	40 mg	capsule	02558424